iBio-610 plus semaglutide preserves lean mass in eight-week obese NHP study
IBIO•iBio said IBIO-610 plus semaglutide preserved lean mass in an eight-week study in obese nonhuman primates, with fat accounting for 93% of weight lost. IBIO-610 reduced active activin E by 97% at week eight, and iBio expects to start first-in-human trials in the first half of 2027.
1. Study findings
iBio said IBIO-610 plus semaglutide preserved lean mass in an eight-week study in obese nonhuman primates. Fat accounted for 93% of weight lost at week eight, while IBIO-610 demonstrated a 97% reduction in active activin E.
2. Trial timing
The company expects to start first-in-human trials of IBIO-610 in the first half of 2027.
